When comparing our study with other studies that examined the seroprevalence of the general population, community pharmacists appear to have a much greater seroprevalence (14.6% vs. for IgM, IgG, or both. Survey data exposed a statistically significant association (< 0.05) between a positive antibody test and direct contact with a person who tested positive for COVID-19 (odds percentage: 2.65 [95% CI: 1.18C5.95]), but there were no statistically significant effects related to the place of work, including PPE use, staff role, or the number of hours worked. The self-reported loss of taste or smell was the only significant symptom associated with a positive antibody test (18.91 [3.10C115.59]). Summary Community pharmacy staff may be at an increased risk for SARS-CoV-2 exposure compared with the general human population. Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), offers disrupted societies worldwide. Studies have shown that after initial exposure to SARS-CoV-2, IgM antibodies 1st appear within 1-2 weeks and are then followed by more durable IgG G15 antibodies within approximately 2-4 weeks.1 Evidence has shown that SARS-CoV-2 IgG is detected by antibody checks for more than 50 days after sign onset, whereas IgM commonly falls below the limits of detection approximately 36 days after sign onset.1 Currently, it is unfamiliar if antibodies for SARS-CoV-2 provide long-term immunity against COVID-19. Health care workers have continued to work on the front lines to serve their individuals during the COVID-19 pandemic. Studies have investigated the presence G15 of SARS-CoV-2 antibodies as an indication of health care exposure to the virus. A wide range of seroprevalence among frontline health care providers have been reported: 7.6% in Nashville, 36% in New York City, G15 44% in London, and 4.9% in Michigan.2, 3, 4, 5 Most Rabbit polyclonal to pdk1 studies have found that health care companies have a greater seropositivity than the estimated general human population ranging from 2.8% to 6.9%.6, 7, 8, 9 Community pharmacy staff, much like other health care workers, have been deemed essential workers and have continued to serve their individuals. During the COVID-19 pandemic, pharmacies have been called on to increase their tasks within areas through the development of immunization methods, SARS-CoV-2 screening, and point-of-care screening.10, 11, 12 Despite the improved exposure, little is known about the risk of SARS-CoV-2 illness among pharmacy staff. At the time of writing this short article, no study has been carried out to estimate the risk of illness of SARS-CoV-2 among this group of health care workers. Although quick SARS-CoV-2 antibody checks are available through the Food and Drug Administration (FDA) under Emergency Use Authorizations, at the time of writing, only 1 1 SARS-CoV-2 antibody test had been authorized for point-of-care screening under a Clinical Laboratory Improvement Amendments (CLIA) waiver.13 However, FDA does not require screening to be done under a CLIA waiver if the screening is done for surveillance purposes through a health department. Objective The purpose of this observational study was to statement the prevalence of antibodies to SARS-CoV-2 from a sample of North Dakota community pharmacy staff. Methods An observational study was conducted analyzing the prevalence of SARS-CoV-2 antibodies among a convenience sample of community pharmacy staff in the towns of Fargo and Grand Forks, ND. At the time of conducting this study (July 2020), these 2 towns were the highest populated towns within North Dakota and located in the counties with the highest quantity of COVID-19 instances.14 , 15 The SARS-CoV-2 antibody test, BioSys In addition (BioSys Laboratories), and relevant materials were provided from your North Dakota Division of Health to conduct this study for monitoring purposes. 16 This study was authorized through the North Dakota State University or college Institutional Review Table. The BioSys Plus COVID-19 IgM/IgG Quick Test was offered an Emergency Use Authorization by FDA but was not CLIA-waived at the time of study.16 It is a lateral flow immunoassay for the qualitative detection and differentiation of IgG and IgM antibodies in whole blood.16 The reported clinical sensitivity and specificity of the test are 93.5% and 100%, respectively.16 The sample requires approximately 20 L of blood and is from the finger using a single-use lancet and pipet. Results of the G15 antibody test can be read between 10 and quarter-hour.16 All community pharmacy staff in Fargo or Grand Forks were.